BioNTech Hits Record as Vaccine Success Spurs on Biotechs
(Bloomberg) -- BioNTech SE, the vaccine maker partnered with Pfizer Inc. on its Covid-19 shot, rose 10% on Monday as the stock rallied past $200 a share, breaking yet another record after closing at new highs four out of five days last week.
The German company was among the top gainers as the biotech sector regained lost footing and optimism about economies reopening bolstered stocks. Shots from Pfizer and BioNTech as well as Moderna Inc. have helped the U.S. reach more than 245 million doses administered, while side-stepping some of the safety concerns that have arisen for shots from AstraZeneca Plc and Johnson & Johnson.
The biotech sector is bouncing back after hitting a four-month low in early April on regulatory concerns related to industry consolidation, new drug applications and potential legislation to rein in the cost of prescriptions. The Nasdaq Biotech Index is up 5.6% from an April 12 trough while the broader market climbed 1.6%. Returns for the biopharma benchmark still trail S&P 500 stocks for the year.
“Vaccines are winning,” Raymond James analysts led by Chris Meekins said in a note to clients. In the U.S., infections, death and hospitalizations are still moving in the right direction, with cases now at their lowest seven-day average since early October. But other parts of the world like India are still suffering amid a massive resurgence in infections, they added.
First-quarter earnings from Pfizer on Tuesday before the stock market opens could provide a further boost for the German biotech. Morgan Stanley expects the pharmaceutical heavyweight to “significantly raise” its vaccine sales expectations for the year and forecasts they could top $19 billion in 2021. Pfizer closed 3.1% higher on Monday for the biggest gain since Dec. 8 after the Biden administration said it will support its move to begin exporting U.S.-made doses of its coronavirus vaccine.
Moderna also jumped 4% Monday, topping its record closing high of $185.98.
Other companies waiting on critical data on their Covid-19 inoculations were mixed, including CureVac NV which rose about 2.8% while Novavax Inc. slumped 18% as investors continue to wait for its Covid vaccine data results that were expected last month.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.